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Hypertrophic Obstructive Cardiomyopathy: Acute Results and
3-Month Follow-Up in 25 Patients
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DIETER FASSBENDER, MD, HENNING K. SCHMIDT, MD, STEFAN STRICK, MD
Bad Oeynhausen, Germany
Objectives. We report the acute results and midterm clinical
course after percutaneous transluminal septal myocardial abla-
tion (PTSMA) in symptomatic patients with hypertrophic ob-
structive cardiomyopathy (HOCM).
Background. In the treatment of HOCM, surgical myectomy
and DDD pacemaker therapy are considered the standard proce-
dural extensions to drug therapy with negatively inotropic drugs.
As an alternative nonsurgical procedure for reducing the left
ventricular outflow tract (LVOT) gradient, PTSMA by alcohol-
induced septal branch occlusion was introduced. However, clinical
follow-up has not been sufficiently described.
Methods. In 25 patients (13 women, 12 men; mean [6SD] age
54.7 6 15.0 years) who were symptomatic despite sufficient drug
therapy, 1.4 6 0.6 septal branches were occluded with an injection
of 4.1 6 2.6 ml of alcohol (96%) to ablate the hypertrophied
interventricular septum. After 3-months, follow-up results of
LVOT gradients and clinical course were determined.
Results. The invasively determined LVOT gradients could be
reduced in 22 patients (88%), with a mean reduction from 61.8 6
29.8 mm Hg (range 4 to 152) to 19.4 6 20.8 mm Hg (range 0 to 74)
at rest (p < 0.0001) and from 141.4 6 45.3 mm Hg (range 76 to
240) to 61.1 6 40.1 mm Hg (range 0 to 135) after extrasystole. All
patients had angina pectoris for 24 h. The maximal creatine
kinase increase was 780 6 436 U/liter (range 305 to 1,810) after
11.1 6 6.0 h (range 4 to 24). Thirteen patients (52%) developed a
trifascicular block for 5 min to 8 days requiring temporary (n 5
8 [32%]) or permanent (DDD) pacemaker implantation (n 5 5
[20%]). An 86-year old woman died 8 days after successful
intervention of uncontrollable ventricular fibrillation in conjunc-
tion with beta-sympathomimetics in chronically obstructive pul-
monary disease. The remaining patients were discharged after
11.3 6 5.4 days (range 5 to 24), after an uncomplicated hospital
course. Clinical and echocardiographic follow-up was achieved in
all 24 surviving patients after 3 months. No cardiac complications
occurred. Twenty-one patients (88%) showed clinical improve-
ment, with a New York Heart Association functional class of 1.4 6
1.1. A further reduction in LVOT gradient was shown in 14
patients (58%).
Conclusions. PTSMA of HOCM is a promising nonsurgical
technique for septal myocardial reduction, with a consecutive
reduction in LVOT gradient. Possible complications are trifas-
cicular blocks, requiring permanent pacemaker implantation, and
tachycardiac rhythm disturbances. Clinical long-term observa-
tions of larger patient series and a comparison with conventional
forms of therapy are necessary to determine the conclusive
therapeutic significance.
(J Am Coll Cardiol 1998;31:252–8)
©1998 by the American College of Cardiology
Hypertrophic obstructive cardiomyopathy (HOCM) is defined
as a primary, sometimes familial and genetically determined
(1,2), myocardial hypertrophy, with a dynamic outflow tract
obstruction of the left and, occasionally, the right ventricle.
Besides the asymmetric hypertrophy of the ventricular myo-
cardium, frequently favoring the interventricular septum
(IVS), it is often possible to observe changes in the papillary
muscles and mitral valve (3). HOCM is the most frequent
cause of stress-induced syncope or sudden cardiac death in
patients ,30 years old (4). Therapeutic approaches aim to
reduce the extent of the outflow tract obstruction, thus improv-
ing clinical symptoms. Negatively inotropic substances (beta-
adrenergic blocking agents [5–7] and calcium antagonists of
the verapamil type [6,8]), the implantation of a DDD pace-
maker (9–11), as well as surgical myectomy (12–20) have all
been used successfully. Through transitory balloon occlusions
of a septal branch, a reduction in the intraventricular gradient
could be established in individual cases (21,22). In 1995, as a
result of these positive experiences, Sigwart (22) was the first to
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describe the successful nonsurgical ablation of hypertrophied
septal myocardium in three patients, with a consecutive de-
crease in the obstruction, later to be followed by other
investigators (23–26). We report the hemodynamic acute and
3-month follow-up results in 25 patients who were treated with
this new procedure.
Methods
Patients. Between January and August 1996, we treated 25
patients (13 women, 12 men; mean age 54.7 6 15.0 years) with
a mean [6SD] disease duration of 7.4 6 4.0 years. The patients
were all symptomatic despite therapy with verapamil or beta-
blockers; the mean New York Heart Association functional
class was 2.8 6 0.6. Three patients, who had shown clinical
improvement after an operative myectomy 7 to 10 years
earlier, had once more become symptomatic; in one of these
patients, even the implantation of a DDD pacemaker had not
led to a decrease in symptoms. The clinical baseline data of the
patients are shown in Table 1.
After initial reports about the potential of nonsurgical
catheter treatment for their clinical symptoms (22), the viabil-
ity and novelty of this therapeutic procedure were explained to
the symptomatic patients. They gave their written consent to
the procedure but not before they had been informed about all
other possible forms of therapy.
In all patients, the diagnosis HOCM was confirmed by
clinical and noninvasive criteria. Before as well as 4 to 6 days
after the intervention, the systolic pressure gradient of the left
ventricular outflow tract (LVOT) was determined by Doppler
echocardiography, both with medication and after a 24-h
washout phase. Using echocardiography, the end-diastolical
thicknesses of the left ventricular posterior wall (LVPW) and
IVS were measured, as well as the dimensions of the left
atrium (LA), left ventricular end-diastolic diameter (LVEDD)
and left ventricular end-systolic diameter (LVESD). The ex-
tent of the occurrence of the systolic anterior movement of the
mitral valve (SAM) phenomenon was classified as follows: 0 5
no SAM phenomenon; I 5 SAM phenomenon without contact
with the IVS; II 5 SAM phenomenon with short-term systolic
contact with the IVS; III 5 SAM phenomenon with holosys-
tolic septal contact. These measurements were carried out
before and 4 to 6 days as well as 3 months after percutaneous
transluminal septal myocardial ablation (PTSMA).
After both noninvasive and invasive preinterventional diag-
noses that excluded an aortic valve gradient and coronary
artery disease, as well as a 24-h medication break, the inter-
vention was carried out. Only two highly symptomatic patients
underwent the examination with continued verapamil therapy.
First, a 4F pacemaker lead was placed through the left femoral
vein in the right ventricle. After puncture of the right femoral
vein, a Brockenbrough catheter was introduced into the left
ventricular inflow tract through the mitral valve, after trans-
septal puncture. After puncture of the right femoral artery, a
7F or 8F guiding catheter was placed into the ascending aorta.
The LVOT gradient was then determined at rest, after the
Valsalva maneuver, after extrasystole and, in some cases, after
wing provocation with orciprenaline. This was followed by the
intravenous application of 10,000 U of heparin to prevent
thromboembolic complications. The standard premedication
usual for coronary dilation, namely, 500 mg of acetylsalicylic
acid, was only administered to the first seven patients. The left
main coronary artery was then intubated and visualized (Fig.
1A), after which the first septal branch was probed with a
0.014-in thick guide wire. Then, an over the wire angioplasty
catheter with a balloon diameter and length of 2.5 mm and
0.4 cm (Atlantis) or 2.0 mm and 1.0 cm (Cobra, Boston
Scientific Corp.), respectively, was placed in the proximal part
of the septal branch. After the balloon was inflated to a
pressure of 6 bar, the correct balloon position was determined
using an injection of contrast medium into the left coronary
Abbreviations and Acronyms
CK 5 creatine kinase
HOCM 5 hypertrophic obstructive cardiomyopathy
IVS 5 intraventricular septum
LA 5 left atrium
LVEDD 5 left ventricular end-diastolic diameter
LVESD 5 left ventricular end-systolic diameter
LVOT 5 left ventricular outflow tract
LVPW 5 left ventricular posterior wall
PTSMA 5 percutaneous transluminal septal myocardial
ablation
SAM 5 systolic anterior movement of the mitral valve
Table 1. Baseline Clinical Characteristics of 25 Patients Undergoing
Catheter Therapy for Hypertrophic Obstructive Cardiomyopathy
Age (yr) 54.7 6 14.9
Range 31–86
Men/women 12/13
History (yr) 7.4 6 4.0
Range 1–13
Malignant family history* 10
Previous surgical myectomy 3
Previous DDD pacemaker 2
Systemic hypertension 1
Medication
Calcium antagonists 17
Beta-blockers 7
Previous complications
Syncope 11
Paroxysmal supraventricular tachycardia 10
Symptomatic bradycardia 1
Cardiac decompensation 6
Stroke 2
NYHA functional class 2.8 6 0.6
Range 2–4
Chest X-ray: CTR 0.52 6 0.07
Range 0.41–0.67
*Premature sudden cardiac death of relatives. Data presented are mean
value 6 SD, range or number of patients. CTR 5 cardiothoracic ratio; NYHA 5
New York Heart Association.
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main artery (Fig. 1B), and the supply area of the septal branch
was determined using an injection of contrast medium through
the balloon catheter (Fig. 1C). If a reduction in the outflow
tract obstruction could be established after 5 min of septal
occlusion, myocardial ablation of the septal branch supply area
was then carried out by an injection of 96% alcohol. Ten
minutes later, the balloon catheter was deflated, and the
morphologic result was examined by visualizing the left main
coronary artery (Fig. 1D). If a sufficient reduction in the
outflow tract gradient through the occlusion of a smaller septal
branch proved impossible to attain, then another septal branch
was occluded. After renewed determination of the LVOT
gradient (Fig. 2), the investigation was brought to an end.
Postinterventional monitoring of the patients was carried
out in the intensive care unit. The vascular sheaths were
removed after normalization of the coagulation variables.
Intensive care included both electrocardiographic monitoring
and determination of creatine kinase (CK) and CK-MB frac-
tion values every 4 h, followed by daily electrocardiographic
checkups and, before discharge from hospital, ergometry. The
corrected QT interval (QTc) was estimated according to the
Bazett formula: QTc 5 QT/RR interval22.
After 3 months, all patients underwent clinical and nonin-
vasive follow-up examinations. Eighteen patients were addi-
tionally examined invasively.
Statistics. Continuous variables are expressed as mean
value 6 SD. Frequencies are given for discrete variables.
Comparison of continuous variables at various times was
carried out using the paired Student t test. A p value ,0.05 was
considered statistically significant. Statistical analyses were
performed using the program Winstat 3.1.
Results
Acute results. Technical course of the treatment. During
the intervention, a mean of 1.4 6 0.6 (range 1 to 3) septal
branches were occluded by injection of 4.1 6 2.6 ml (range 1.5
to 11.0) of alcohol. Having occluded a septal branch with an
insufficient gradient reduction in one female patient with a
previous operative myectomy, it was not possible successfully
to probe a second branch with the balloon catheter. After
stopping the procedure because of its long duration and high
consumption of contrast medium, this branch could be probed
and occluded without any problems in a second session, with a
complete reduction of the LVOT gradient. The mean cathe-
terization time was 101.8 6 33.3 min (range 46 to 173), with a
mean radiation time of 18.4 6 12.7 min (range 5.6 to 44.5);
Figure 1. A, Left main coronary artery visualized laterally before
therapy, showing large first septal branch (arrow). B, After inflation of
the balloon catheter, the optimal position of the balloon (arrow) in the
proximal part of the septal branch was determined. C, With an
injection of contrast medium through the balloon catheter, the supply
area of the septal branch was determined (arrow). D, Final visualiza-
tion of the vessel stump (arrow) of the occluded septal branch.
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253.1 6 121.2 (range 130 to 550) ml of contrast medium was
required.
Hemodynamic results. A reduction in LVOT gradient could
be attained in 22 patients (88%): complete reduction in 4
(16%), .50% in 16 (64%) and 20% to 49% in 2 (8%). During
the first intervention in three patients (12%), a gradient
reduction could not be attained; however, a second interven-
tion was successful in all three. The mean systolic pressure
difference in the LVOT at rest sank from a mean of 61.7 6
29.8 mm Hg (range 4 to 152) to 27.2 6 19.0 mm Hg (range 1
to 67, p , 0.0001) after exploratory balloon occlusion and after
occlusion by alcohol to 19.4 6 20.8 mm Hg (range 0 to 74, p ,
0.0001 vs. baseline, p 5 0.015 vs. balloon occlusion). The
predictive value of the balloon-induced LVOT gradient reduc-
tion for the final result was not always low (Postprocedural
LVOT gradient 5 21.09 1 0.71 3 LVOT gradient after
balloon occlusion; r 5 0.70). The postextrasystolic gradient
could be reduced from 141.4 6 45.3 mm Hg (range 76 to 240)
before therapy to 61.1 6 40.1 mm Hg (range 8 to 135, p ,
0.0001). During the Valsalva maneuver, the LVOT gradient
sank from 108.3 6 35.7 mm Hg (range 38 to 188) to 39.4 6
32.6 mm Hg (range 0 to 119, p , 0.0001).
Echocardiographic course. Both at rest and during the
Valsalva maneuver, LVOT gradients were significantly re-
duced (Fig. 3). The mean SAM phenomenon was acutely
reduced from 2.4 6 0.8 (range 1 to 3) to 1.6 6 1.0 (range 0 to
3, p , 0.001). At final echocardiography, new wall motion
dyskinesia could be seen in the basal septum in all patients.
Electrocardiographic changes. During ablation, persistent
broadening of the QRS complex and temporarily lengthened
QTc intervals could be observed in all patients. In addition, a
trifascicular block occurred during intervention in 13 patients
(52%); which made temporary pacemaker stimulation neces-
sary in 8 (32%) and permanent (DDD) pacemaker stimulation
necessary in 5 (20%). In 13 patients (52%), new bundle branch
block patterns could be observed (Table 2).
Clinical course. During the alcohol injection, all patients
complained of a marked feeling of pressure in the left thorax,
making administration of 0.3 mg of buprenorphine necessary
in 24 patients. Postinterventionally, patients reported a feeling
of pressure in the thorax lasting up to 24 h. After a mean
duration of 11.1 6 5.9 h, a maximal increase in CK to 780.0 6
427.3 U/liter (range 305 to 1,810) was registered, with an MB
fraction of 102.8 6 63.4 U/liter (range 45 to 281). The patients
were monitored in the intensive care for 5.0 6 3.3 days (range
2 to 14). Twenty-four patients could leave the hospital after
11.3 6 5.4 days (range 5 to 24), after a cardially uncomplicated
Figure 3. Doppler echocardiographically estimated LVOT gradients
before, immediately after and 3 months after PTSMA at rest and
during the Valsalva maneuver.
Figure 2. Pressure curves of the left ventricular
inflow tract (LV) and the aorta (Ao) before (a) and
after (b) occlusion of the septal branch, with com-
plete reduction of LVOT gradient. Prolongation of
the QRS complex and PQ and QT intervals is seen
on the electrocardiogram after PTSMA.
255JACC Vol. 31, No. 2 SEGGEWISS ET AL.
February 1998:252–8 CATHETER TREATMENT FOR HOCM
course. Drug treatment was continued in all patients, compris-
ing low dose beta-blockers (n 5 19) or verapamil (n 5 5).
Complications. During the intervention, two patients devel-
oped ventricular fibrillation before the alcohol injection. In
both patients, sinus rhythm could be established by single 300-J
defibrillation. In one patient, the fibrillation was caused by the
occlusion of the left main coronary artery by the 8F guiding
catheter; after defibrillation, a catheter with side holes was
used without any further problem. In the second patient, the
cause was mechanical irritation through the extremely distally
positioned guide wire. One 86-year old female patient, in
whom the therapy had been carried out with a good hemody-
namic acute result after several previous cardiac decompensa-
tions, died 8 days after the intervention, at the end of a clinical
course that up to then had been uneventful, of the conse-
quences of uncontrollable ventricular fibrillation. We traced
this event to an overdose of beta-sympathomimetics in con-
junction with known chronic obstructive pulmonary disease. In
another female patient, gastrointestinal bleeding after an
erosive gastritis was an extracardial complication during the
clinical course. A blood transfusion was not necessary. We
observed no neurologic complications.
Three-month follow-up. Clinical course. After 3 months, a
clinical follow-up examination was carried out in all 24 surviv-
ing patients. At this time, there was a significant improvement
in the clinical symptoms, with the mean functional class rising
to 1.2 6 0.8 (p , 0.001 vs. baseline). Twenty-one patients
(88%) had improved subjectively; 3 patients (12%) reported
no change in their cardiac symptoms; and 6 patients (25%)
were able to tolerate a maximal stress load. Exercise capacity
during ergometry increased from 67.0 6 73.5 W (before
PTSMA) to 110.7 6 49.7 W (p 5 0.008). There were no cardiac
complications during follow-up. Three patients with unsatis-
factory primary results underwent successful intervention at
that time.
Echocardiographic course. Echocardiographic results could
be compared in all 24 patients. In eight patients (34%), there
was complete reduction of the LVOT gradient. Compared with
baseline values, 13 patients (54%) had a reduction of LVOT
gradient .50%, whereas 3 (12%) showed no significant
change. Compared with the acute results, a further reduction
in LVOT gradient had occurred in 14 patients (58%) and a
renewed increase in 1 (4%). In 8 patients (34%), no further
change had occurred. The need of DDD pacemaker implan-
tation after PTSMA had no influence on the results. Mean
LVOT gradient, both at rest (p 5 0.008) and during the
Valsalva maneuver (p 5 0.011), had significantly decreased
compared with that directly after the intervention (Fig. 3). The
changes in left heart dimensions are shown in Table 3.
Hemodynamic course. In 18 patients (75%), recatheteriza-
tion was carried out in addition to the noninvasive checkup.
The six remaining patients did not consent to invasive diag-
nostic procedures because of the significant decrease in their
symptoms. There was complete reduction of the LVOT gradi-
ent in eight patients with recatheterization (45%), six of whom
(33%) demonstrated a reduction of .50% of their original
values. Compared with the acute hemodynamic result after
septal occlusion, a further reduction of the gradient could be
observed in seven patients (39%). In eight patients (44%), no
further change had occurred, but in three (17%), the gradient
had increased. In these three patients, repeat PTSMA was
successful. Compared with those directly after intervention, the
mean values had not significantly changed, either at rest (18.4 6
28.0 mm Hg) or after extrasystole (47.8 6 45.1 mm Hg). The
reduction in left ventricular end-diastolic pressure from 21.6 6
7.9 mm Hg (before intervention) to 19.1 6 7.2 mm Hg (3 months
after intervention) was not significant because of the low number
of patients examined. No change in global left ventricular ejection
fraction could be observed in any patient, whereas all patients
demonstrated limited akinesia of the basal septum and occluded
septal branches.
Discussion
HOCM was first described as a disease entity in its own
right in the late 1950s (27). A morphologic difference is made
between subaortic obstruction and the far more rare midven-
tricular obstruction (3). Patients become symptomatic in the
form of angina pectoris, dyspnea, stress-induced syncope or
heart failure caused by diastolic and systolic dysfunction. Atrial
fibrillation, ventricular tachycardia (28,29) and myocardial
scintigraphic proof of ischemia (30) are all prognostically
unfavorable factors. Evaluation of the prognostic significance
of LVOT obstruction varies (6,31–33).
Table 2. Bundle Branch Blocks After Percutaneous Transluminal
Septal Myocardial Ablation
Bundle Branch Block
No. of
Patients
Trifascicular 13
Temporary 8
Permanent 5
Left bundle 2
Right bundle 6
Right bundle and left anterior bundle 3
Right bundle and left posterior bundle 1
Left anterior bundle 1
Table 3. Comparison of Echocardiographic Variables Before
(baseline) and Three Months (follow-up) After Percutaneous
Transluminal Septal Myocardial Ablation
Baseline
Follow-
Up p Value
LA (mm) 48.0 6 8.1 45.7 6 8.1 0.04
LVEDD (mm) 46.6 6 5.3 48.8 6 6.1 0.08
LVESD (mm) 27.2 6 5.0 30.8 6 6.6 0.01
IVS (mm) 21.9 6 3.5 17.0 6 6.5 , 0.0001
LVPW (mm) 14.3 6 2.6 12.3 6 5.5 0.09
SAM 2.4 6 0.8 0.7 6 0.9 , 0.0001
Data presented are mean value 6 SD. IVS 5 interventricular septum; LA 5
left atrium; LVEDD 5 left ventricular end-diastolic diameter; LVESD 5 left
ventricular end-systolic diameter; LVPW 5 left ventricular posterior wall;
SAM 5 septal anterior movement of mitral valve.
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Previous forms of therapy for HOCM. Treatment of symp-
tomatic patients with HOCM aims at reducing the outflow
tract gradient. This reduction in LVOT obstruction could be
achieved with drug therapy through the administration of
negatively inotropic substances, especially beta-blockers (5–7)
and calcium antagonists of the verapamil type (6,8). The
implantation of a DDD pacemaker system was able to reduce
the outflow tract gradient by .30% (9–11), also leading to a
decrease in symptoms in patients without altering septal
thickness. However, when determining the optimal atrioven-
tricular interval, it is important not to hinder sufficient left
ventricular filling by shortening the atrioventricular activation
time too drastically (34). Because of these restrictions, DDD
pacemaker therapy still cannot be generally recommended (35).
Surgical therapy gained increasing significance after its
introduction by Cleland in 1958 (12–20). The operative proce-
dure is complicated by a high mortality rate of 1.6% to 10.0%
and the possibility of perioperative complications, such as the
emergence of a ventricular septal defect, total atrioventricular
block and cerebral embolism, particularly in connection with
an intraoperative myectomy. When perioperative mortality
was not considered, a prognostic improvement was achieved in
postoperative patients compared with patients treated conser-
vatively with drug therapy, so that extension of the indication
for operative myectomy to low level symptomatic patients was
discussed as early as 1983 (14).
Results of PTSMA. After first investigations in patients
with HOCM were able to establish a reduction in intracavitary
pressure gradient through transitory occlusion of a septal
branch (21,22), Sigwart (22) was then the first to report a
successful nonsurgical myocardial reduction in cases of HOCM
through occlusion of the septal branch using pure alcohol.
After we successfully completed our initial experience with this
technique in six patients (25), we considered it feasible for use
in a larger patient population.
The chemical ablation procedure had been previously de-
scribed for treatment of ventricular arrhythmia (36). Similar to
the surgical technique, this method aims to achieve a reduction
in septal muscular mass through a limited therapeutic infarc-
tion, thus reducing the extent of the outflow tract obstruction.
Compared with the surgical procedure, a significant advantage
is that through occlusion of the septal branch, the therapeutic
effect may be predicted and with a nondetectable reduction in
the outflow tract gradient, chemical occlusion of the septal
branch need not be carried out. However, our results lead us to
conclude that the significance of transitory balloon occlusion
for prediction of acute hemodynamic results is not very high.
Particularly in patients with several small septal branches, the
difficulty of this procedure lies in identifying the septal branch
supplying the myocardial area responsible for the existence of
the outflow tract obstruction. As initial experiences have
shown, myocardial contrast echocardiography could be helpful
here (37). This procedure may also lead to septal branches that
atypically originate from side branches of the left anterior
descending coronary artery being identified as responsible for
supplying the septal area responsible for gradient formation.
In the series presented here, a complete reduction in LVOT
gradient could be achieved in 4 patients (16%) and a reduction
of .50% in 16 (64%). In two patients (8%), the acute
reduction was 20% to 49%. Short-term follow-up observations
show that a further reduction in LVOT gradient may be
expected in the subsequent course in .50% of patients. This is
presumably due to a remodeling process comparable to that
after acute myocardial infarction. The ongoing reduction of
the SAM phenomen may be another reason for the progressive
LVOT gradient reduction.
We were also able to show that PTSMA can be easily
repeated in case of an initial failure. In three patients (12%),
LVOT gradient reduction could not be achieved on the first
attempt. In one female patient with a previous operation, in
whom a second septal branch could not be reached with the
balloon catheter during the first intervention because of tech-
nical problems, a hemodynamically and clinically good acute
result could be achieved with a second intervention. In the
other two patients who could not be treated successfully during
the first intervention, the LVOT gradient was reduced by
means of intraoperative myocardial contrast echocardiography
at the 3 month follow-up catheterization.
The observation of further gradient reduction over the
short-term course due to remodeling after induced therapeutic
infarction, as well as the nonproblematic repeatability of
PTSMA, render a staged procedure preferable, if several
slender septal branches are present, to reduce the theoretic
risk of systolic dysfunction through the loss of a large propor-
tion of septal myocardium.
As with any new therapeutic procedure, the PTSMA of
HOCM presented here is essentially limited by the occurrence
of significant complications. After induction of a therapeutic
limited myocardial infarction, all patients had symptoms of
angina pectoris for a period of 24 h. The most frequent
complication observed to date has been trifascicular blocks,
which occurred in 60% of patients and made a permanent
pacemaker necessary in 20%. For such patients, implantation
of a DDD pacemaker system is recommended, such that
atrioventricular activation time is optimized, as described
earlier. A larger series of patients help to identify those
patients requiring definitive pacemaker implantation as early
as possible to reduce the hospital stay.
To avoid potential tachycardial arrhythmias in conjunction
with an acute infarction, as seen in our 86-year old female
patient, monitoring of rhythm is necessary for several days. It
should be noted, that acute ventricular rhythm disturbances
were not seen during alcohol injection. As with surgical
therapy, the possibility of ventricular septal defect formation
must also be considered. To reduce the risk of acute compli-
cations, it may be helpful to minimize the ablated septal area
by using myocardial contrast echocardiography.
The long-term effects of the present therapeutic procedure
on ventricular function and prognosis of the primary disease
are not predictable. Because the primary disease is accompa-
nied by restricted diastolic ventricular function, we currently
consider permanent medical therapy with low dose beta-
blockers or calcium antagonists to be necessary. In addition,
clinical follow-up observations must confirm whether the fa-
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vorable midterm results reported here and elsewhere (38) can
be confirmed over the long term.
Conclusions. These initial results confirm the experience
of Sigwart (22) and show that the new interventional technique
represents a promising alternative to the previous treatment of
HOCM and is able, insofar as clinical symptoms are con-
cerned, to achieve results equally as good as surgical myocar-
dial resection and probably equally as good or even better
results than pacemaker therapy. Possible complications are
trifascicular blocks requiring permanent pacemaker implanta-
tion and tachycardiac rhythm disturbances. Long-term effects
of the procedure on the prognosis of the patients and left
ventricular function remain to be investigated in prospective
studies. Finally, PTSMA has to be compared with myectomy
and DDD pacemaker therapy in a prospective, randomized
trial to estimate its definitive significance in the treatment of
symptomatic patients with HOCM.
We thank Sarah L. Kirkby for linguistic assistance in the preparation of the
manuscript.
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